Summary

KEY FINDINGS
The China dry eye disease market is expected to record a CAGR of 6.04% during the forecast period, 2023-2030. As per independent research, the incidence rate of dry eye disease in China is 25%-30%.
MARKET INSIGHTS
In China, according to a 2021 study in the BMC Ophthalmology journal, the prevalence of dry eye disease is around 21.6%, with a higher prevalence in urban areas than in rural areas. In addition, the study found that the prevalence was higher in females as compared to males. Accordingly, product developments and trials by key companies are expected to boost market growth prospects in China.
For instance, in 2021, Zhaoke Ophthalmology disclosed its Phase III clinical study for the company’s key drug candidate, Cyclosporine A (CsA) Ophthalmic Gel, intended to treat dry eye disease. The China dry eye disease market segmentation includes distribution channel, product, and type. The product segment includes secretagogues, artificial tears, punctual plugs, anti-inflammatory drugs, and other products. Punctual plugs are biocompatible devices that are inserted in the tear duct to block drainage. There are two types of tear duct plugs, dissolvable and semi-permanent.
COMPETITIVE INSIGHTS
Some of the eminent companies in the market include Otsuka Pharmaceutical Co Ltd, Bausch Health Companies Inc, Johnson & Johnson, Sentiss Pharma Private Limited, Novartis AG, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS
3.2.2. SUBSTITUTE THERAPIES
3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. MARKET CONCENTRATION ANALYSIS
4.5. VALUE CHAIN ANALYSIS
4.5.1. RESEARCH AND DEVELOPMENT
4.5.2. MANUFACTURING
4.5.3. DISTRIBUTORS
4.5.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.1.4. BUSINESS EXPANSIONS & DIVESTITURES
8.2. COMPANY PROFILES
8.2.1. ALCON
8.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
8.2.3. BAUSCH HEALTH COMPANIES INC
8.2.4. JOHNSON & JOHNSON
8.2.5. NOVARTIS AG
8.2.6. OTSUKA PHARMACEUTICAL CO LTD
8.2.7. SENTISS PHARMA PRIVATE LIMITED